Safety and efficacy of pralsetinib in RET fusion-positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial.
暂无分享，去创建一个
Y. Houvras | A. Mansfield | J. Mazières | J. Lin | G. Kalemkerian | D. Bowles | V. Subbiah | C. Baik | J. Gainor | F. Griesinger | D-W. Kim | D. Lee | A. van der Wekken | D. Misch | D. Lee | E. Garralda | G. Curigliano | J. J. Lin | L. Paz-Ares | S.V. Liu | D. Tan | V. Smoljanović | S. Liu | M. Louie-Gao | D. Kim | A. Boral | M. Thomas | A. J. van der Wekken | A. Rahman | S. Kong | A. Zalutskaya